Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jun;83(8):725-729.
doi: 10.1007/s40265-023-01874-9.

Omaveloxolone: First Approval

Arnold Lee  1
Affiliations
Review

Omaveloxolone: First Approval

Arnold Lee. Drugs. 2023 Jun.

Abstract

Omaveloxolone (SKYCLARYS™) is an orally active, small molecule semi-synthetic triterpenoid drug that increases antioxidant activity, which is being developed by Reata Pharmaceuticals, Inc. for the treatment of Friedreich's ataxia. In patients with Friedreich's ataxia, the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway is suppressed, which is associated with oxidative stress, mitochondrial dysfunction and damage to cells, including central and peripheral neurones. The Nrf2 pathway may be activated by omaveloxolone as it blocks the ubiquitination and degradation of Nrf2. Omaveloxolone was approved in February 2023 in the USA for the treatment of Friedreich's ataxia. This article summarizes the milestones in the development of omaveloxolone leading to this first approval for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.

PubMed Disclaimer

References

    1. US Food & Drug Administration. FDA approves first treatment for Friedreich’s ataxia [media release]. 28 Feb 2023. https://www.fda.gov/ .
    1. Ghanekar SD, Miller WW, Meyer CJ, et al. Orphan drugs in development for the treatment of Friedreich’s ataxia: focus on omaveloxolone. Degener Neurol Neuromuscul Dis. 2019;9:103–7. - PubMed - PMC
    1. Abeti R, Baccaro A, Esteras N, et al. Novel Nrf2-inducer prevents mitochondrial defects and oxidative stress in Friedreich’s ataxia models. Front Cell Neurosci. 2018;12:188. - DOI - PubMed - PMC
    1. Reata Pharmaceuticals, Inc. Reata Pharmaceuticals announces FDA approval of SKYCLARYS(TM) (omavaloxolone), the first and only drug indicated for patients with Friedreichs ataxia [media release]. 28 Feb 2023. https://www.reatapharma.com/ .
    1. Reata Pharmaceuticals, Inc. SKYCLARYS™ (omaveloxolone): US prescribing information. 2023. https://www.fda.gov/ . Accessed Mar 1 2023.

LinkOut - more resources